{
    "nctId": "NCT02781155",
    "briefTitle": "Limiting Chemotherapy Side Effects by Using Moxa",
    "officialTitle": "Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Neoplasms, Colorectal Neoplasms, Genital Neoplasms, Female, Toxicity Due to Chemotherapy",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 25,
    "primaryOutcomeMeasure": "Adherence to moxa regimen assessed by Daily Moxa Diary",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* with breast, gynaecologic, or colorectal cancer who are prescribed radical or adjuvant chemotherapy in the early disease setting, or first or second line chemotherapy is in the metastatic setting\n* about to commence a course of chemotherapy for which granulocyte-colony stimulating factor (G-CSF) is not routinely indicated\n* with a life expectancy of more than six months\n* with blood cell counts within the normal range\n* with calculated creatinine levels of \u2265 50ml/min\n* English speaking\n* able to understand instructions for self-administration of moxibustion and carry out the procedure\n* able to give informed consent\n\nExclusion Criteria:\n\n* having a haematological cancer diagnosis\n* prescribed a chemotherapy regimen for which G-CSF is indicated\n* having third or fourth line chemotherapy\n* having metastatic bone cancer\n* who have concomitant severe medical problems preventing participation\n* with cognitive impairment that would impact participant's ability to safely administer self-moxibustion\n* having renal dysfunction\n* with lymphedema in the lower body.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}